Monday, November 07, 2022 8:13:56 AM
The company's gross revenue of $1.6 million had an increase of 31.2% from Q1 to Q2 with further acceleration expected in Q3 and Q4.
The gross margins increased and we expect the high margin sales to accelerate with our new marketing initiatives.
They drastically decreased their SG&A expenses by $3.4 million in the first half of 2022. The recent cost reductions and operating leverage helped narrow their operating loss by $1.0 million in 2022.
Quote from the CEO on their impressive quarter: "We are seeing positive results from our new marketing initiatives with increasing sales trends in the first six weeks of Q3 as we work to increase our revenues significantly in the second half and should see an additional acceleration in Q4. During Q2 we worked on successfully increasing our gross margins, while we continually work to decrease the SG&A."
https://finance.yahoo.com/news/cure-pharmaceutical-reports-second-quarter-100000381.html
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM